MEREO BIOPHARMA GROUP PLC SECURITIES FRAUD NOTICE: Berger Montague Informs Mereo BioPharma Group plc (MREO) Investors of Securities Fraud Lawsuit

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc on behalf of investors who purchased its American Depositary Shares during the specified class period, alleging misrepresentation of clinical trial results [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Mereo misrepresented the results of the ORBIT and COSMIC Phase 3 programs for setrusumab, a treatment for Osteogenesis Imperfecta [3]. - Investors were informed on December 29, 2025, that neither clinical trial met its primary endpoint, leading to a significant loss of over 87% in the value of Mereo's ADSs in one trading day [3]. Group 2: Company Background - Mereo BioPharma is a UK-based biopharmaceutical company focused on developing therapies for rare and serious conditions [2]. - The company is currently facing legal challenges that may impact its reputation and financial standing in the biopharmaceutical industry [1][3].